International Ophthalmology

, Volume 34, Issue 6, pp 1271–1274 | Cite as

Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye

  • Tryfon Rotsos
  • Chrysanthos Symeonidis
  • Ioanna Triantafillopoulou
  • Spyridon Kanellopoulos
  • Anastasios Kouris
Case Report


A significant therapeutic effect in the fellow eye after intravitreal ranibizumab injections was observed in a 39-year-old diabetic male. The patient was followed-up with fluorescein angiography (FA) and Optical Coherence Tomography (OCT). On referral, best-corrected visual acuity (BCVA) was 6/60 in the right eye and Counting Fingers in the left eye. FA revealed foveal leakage in both eyes. OCT revealed diabetic and cystoid macular edema (DME-CME) in both eyes. The patient was treated with two intravitreal ranibizumab injections in the left eye. BCVA was 6/15 and 6/30 one month after the last injection. OCT revealed significant improvement (DME elimination and significant CME improvement) in both eyes, despite the fact that only the left eye was treated. It is conceivable that, in this eye, chronic vascular damage was limited and a minimal quantity of ranibizumab had a positive effect on vascular permeability, resulting in DME resolution.


Diabetic macular edema Ranibizumab Optical coherence tomography  


  1. 1.
    Romero-Aroca P (2010) Targeting the pathophysiology of diabetic macular edema. Diabetes Care 33:2484–2485PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179–2182PubMedCrossRefGoogle Scholar
  3. 3.
    Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, Campochiaro PA (2009) Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology 116:1748–1754PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K (2011) Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther 27:379–383PubMedCrossRefGoogle Scholar
  5. 5.
    Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803–2812PubMedCentralPubMedGoogle Scholar
  6. 6.
    Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, Kuebler P, Damico-Beyer LA, Joshi A (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54:1616–1624PubMedCrossRefGoogle Scholar
  7. 7.
    Gamulescu MA, Helbig H (2010) Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 26:213–216PubMedCrossRefGoogle Scholar
  8. 8.
    Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB (2010) Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 149:939–946PubMedCrossRefGoogle Scholar
  9. 9.
    Neri P, Mariotti C, Mercanti L, Salvolini S, Giovannini A (2008) Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol 28:425–427PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Tryfon Rotsos
    • 1
  • Chrysanthos Symeonidis
    • 2
  • Ioanna Triantafillopoulou
    • 1
  • Spyridon Kanellopoulos
    • 1
  • Anastasios Kouris
    • 1
  1. 1.Department of OphthalmologyGeneral Hospital of AthensAthensGreece
  2. 2.2nd Department of Ophthalmology, Aristotle University of ThessalonikiPapageorgiou General HospitalThessalonikiGreece

Personalised recommendations